Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
9.08
+0.12 (1.34%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Nuvectis Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Cash & Equivalents | 31.63 | 18.53 | 19.13 | 19.99 | 5.74 | |
| Cash & Short-Term Investments | 31.63 | 18.53 | 19.13 | 19.99 | 5.74 | |
| Cash Growth | 70.69% | -3.10% | -4.34% | 248.19% | - | |
| Other Current Assets | 0.08 | 0.07 | 0.06 | 0.41 | 0.09 | |
| Total Current Assets | 31.71 | 18.61 | 19.19 | 20.41 | 5.83 | |
| Long-Term Deferred Charges | - | - | - | - | 0.82 | |
| Accounts Payable | 6.27 | 2.5 | 2.77 | 2.91 | 1.06 | |
| Accrued Expenses | 7.02 | 6.4 | 4.21 | 2.83 | 0.54 | |
| Other Current Liabilities | - | - | - | 0.45 | 0.82 | |
| Total Current Liabilities | 13.3 | 8.89 | 6.98 | 6.19 | 2.42 | |
| Additional Paid-In Capital | 118.1 | 82.96 | 66.45 | 46.2 | 1.89 | |
| Retained Earnings | -99.69 | -73.25 | -54.25 | -31.99 | -12.9 | |
| Total Common Equity | 18.41 | 9.71 | 12.2 | 14.22 | -11.01 | |
| Total Liabilities & Equity | 31.71 | 18.61 | 19.19 | 20.41 | 6.66 | |
| Net Cash (Debt) | 31.63 | 18.53 | 19.13 | 19.99 | 5.74 | |
| Net Cash Growth | 70.69% | -3.10% | -4.34% | 248.19% | - | |
| Net Cash Per Share | 1.45 | 1.08 | 1.23 | 1.58 | 1.35 | |
| Filing Date Shares Outstanding | 26.49 | 23.39 | 17.77 | 14.75 | 12.72 | |
| Total Common Shares Outstanding | 25.68 | 19.5 | 17.42 | 14.64 | 4.51 | |
| Working Capital | 18.41 | 9.71 | 12.2 | 14.22 | 3.41 | |
| Book Value Per Share | 0.72 | 0.50 | 0.70 | 0.97 | -2.44 | |
| Tangible Book Value | 18.41 | 9.71 | 12.2 | 14.22 | -11.01 | |
| Tangible Book Value Per Share | 0.72 | 0.50 | 0.70 | 0.97 | -2.44 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.